Harrow Health, Inc. (HROW): Price and Financial Metrics
HROW Price/Volume Stats
| Current price | $10.25 | 52-week high | $28.25 |
| Prev. close | $9.87 | 52-week low | $7.60 |
| Day low | $9.86 | Volume | 379,400 |
| Day high | $10.70 | Avg. volume | 352,637 |
| 50-day MA | $9.98 | Dividend yield | N/A |
| 200-day MA | $15.69 | Market Cap | 359.96M |
HROW Stock Price Chart Interactive Chart >
HROW POWR Grades
- HROW scores best on the Growth dimension, with a Growth rank ahead of 50.55% of US stocks.
- HROW's strongest trending metric is Stability; it's been moving down over the last 26 weeks.
- HROW's current lowest rank is in the Stability metric (where it is better than 6.7% of US stocks).
HROW Stock Summary
- With a year-over-year growth in debt of 135.77%, HARROW INC's debt growth rate surpasses 93.62% of about US stocks.
- Over the past twelve months, HROW has reported earnings growth of -133.81%, putting it ahead of merely 9.96% of US stocks in our set.
- HARROW INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -47.76%, greater than the shareholder yield of just 8.27% of stocks in our set.
- Stocks that are quantitatively similar to HROW, based on their financial statements, market capitalization, and price volatility, are DOGZ, ALTO, AMBO, RGF, and SOPA.
- Visit HROW's SEC page to see the company's official filings. To visit the company's web site, go to www.harrowinc.com.
HROW Valuation Summary
- In comparison to the median Healthcare stock, HROW's price/sales ratio is 19.05% lower, now standing at 3.4.
- HROW's price/sales ratio has moved NA NA over the prior 180 months.
Below are key valuation metrics over time for HROW.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| HROW | 2023-12-29 | 3.4 | 5.2 | -27.7 | 101.7 |
| HROW | 2023-12-28 | 3.4 | 5.2 | -27.5 | 101.3 |
| HROW | 2023-12-27 | 3.4 | 5.1 | -27.1 | 100.0 |
| HROW | 2023-12-26 | 3.3 | 5.0 | -26.6 | 98.6 |
| HROW | 2023-12-22 | 3.3 | 4.9 | -26.1 | 97.4 |
| HROW | 2023-12-21 | 3.3 | 4.9 | -26.4 | 98.0 |
HROW Growth Metrics
- Its 3 year price growth rate is now at 38.66%.
- Its 5 year revenue growth rate is now at 134.06%.
- Its 5 year net income to common stockholders growth rate is now at -22.96%.
The table below shows HROW's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 88.454 | 3.927 | -22.559 |
| 2022-06-30 | 84.342 | 2.261 | -24.423 |
| 2022-03-31 | 79.153 | 2.841 | -21.134 |
| 2021-12-31 | 72.476 | 5.082 | -18.479 |
| 2021-09-30 | 66.883 | 6.006 | -9.912 |
| 2021-06-30 | 62.571 | 10.749 | 7.054 |
HROW's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- HROW has a Quality Grade of B, ranking ahead of 89.94% of graded US stocks.
- HROW's asset turnover comes in at 0.893 -- ranking 26th of 682 Pharmaceutical Products stocks.
- CGEN, ADAP, and ACOR are the stocks whose asset turnover ratios are most correlated with HROW.
The table below shows HROW's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.893 | 0.747 | 0.148 |
| 2021-03-31 | 0.943 | 0.722 | 0.201 |
| 2020-12-31 | 0.917 | 0.704 | -0.020 |
| 2020-09-30 | 0.873 | 0.699 | 0.005 |
| 2020-06-30 | 0.861 | 0.680 | -0.359 |
| 2020-03-31 | 0.898 | 0.675 | -0.374 |
HROW Price Target
For more insight on analysts targets of HROW, see our HROW price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $15.13 | Average Broker Recommendation | 1.38 (Strong Buy) |
Harrow Health, Inc. (HROW) Company Bio
Harrow Health, Inc., together with its subsidiaries, develops, produces, and sells medications for unmet needs primarily in the United States. The company primarily provides ophthalmology based formulations to physicians and patients; and sterile and non-sterile compounded medications. It also develops and commercializes therapeutics for treating ocular surface diseases; and non-intravenous sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. Its products portfolio includes topical eye drop drug candidates, including SURF-100 and SURF-200; SURF-300, an oral capsule for treating patients suffering from ocular surface diseases, and DED signs and symptoms; Klarity drops to protect and rehabilitate the ocular surface pathology for patients with DED; MELT-100, a drug that is administered sublingually for conscious sedation during cataract surgery; MAY-66 that is used for the treatment of symptoms associated with Peyronie's disease; MAY-44, a non-estrogen topical analgesic gel; and other drug candidates for rare diseases. In addition, the company engages in the development of MAY-88, an oral anhydrous extend release suspension of pentosan polysulfate sodium for interstitial cystitis. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in San Diego, California.
Latest HROW News From Around the Web
Below are the latest news stories about HARROW INC that investors may wish to consider to help them evaluate HROW as an investment opportunity.
7 Short-Squeeze Stocks That Are Screaming for SpeculationWhile the concept of short-squeeze stocks has been all the rage throughout most of the pandemic-disruption cycle, we may have been doing this all wrong. |
Harrow Completes Transfer of the TRIESENCE® New Drug ApplicationNASHVILLE, Tenn., November 29, 2023--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Application (NDA) for TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL, a synthetic corticosteroid indicated for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids as well as visualization during vitrectomy. |
Harrow to Present at Two Investor Conferences in NovemberNASHVILLE, Tenn., November 20, 2023--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in the following two upcoming conferences: |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayWe're starting off Tuesday with a breakdown of all the biggest pre-market stock movers traders need to know about this morning! |
Harrow Health, Inc. (NASDAQ:HROW) Q3 2023 Earnings Call TranscriptHarrow Health, Inc. (NASDAQ:HROW) Q3 2023 Earnings Call Transcript November 13, 2023 Harrow Health, Inc. misses on earnings expectations. Reported EPS is $-0.13 EPS, expectations were $0.03. Operator: Good afternoon, and welcome to Harrow’s Third Quarter 2023 Earnings Conference Call. My name is Betsy, and I will be your operator for today’s call. At this […] |
HROW Price Returns
| 1-mo | 2.50% |
| 3-mo | -20.08% |
| 6-mo | -39.46% |
| 1-year | -45.22% |
| 3-year | -7.07% |
| 5-year | 68.86% |
| YTD | -8.48% |
| 2023 | -24.12% |
| 2022 | 70.83% |
| 2021 | 25.95% |
| 2020 | -11.83% |
| 2019 | 36.73% |
Continue Researching HROW
Here are a few links from around the web to help you further your research on Harrow Health Inc's stock as an investment opportunity:Harrow Health Inc (HROW) Stock Price | Nasdaq
Harrow Health Inc (HROW) Stock Quote, History and News - Yahoo Finance
Harrow Health Inc (HROW) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...